First Bank & Trust Acquires Shares of 9,164 Castle Biosciences, Inc. (NASDAQ:CSTL)

First Bank & Trust bought a new position in Castle Biosciences, Inc. (NASDAQ:CSTL) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 9,164 shares of the company’s stock, valued at approximately $261,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Acadian Asset Management LLC grew its position in shares of Castle Biosciences by 130.7% during the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after purchasing an additional 119,443 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Castle Biosciences by 116.5% during the 2nd quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after acquiring an additional 114,104 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Castle Biosciences by 249.3% during the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock worth $3,020,000 after purchasing an additional 99,001 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Castle Biosciences by 47.3% in the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock worth $6,564,000 after purchasing an additional 96,800 shares during the last quarter. Finally, Lisanti Capital Growth LLC bought a new stake in Castle Biosciences during the second quarter valued at approximately $2,102,000. Institutional investors own 92.60% of the company’s stock.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 12,989 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $23.06, for a total value of $299,526.34. Following the transaction, the chief operating officer now directly owns 132,836 shares of the company’s stock, valued at approximately $3,063,198.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Derek J. Maetzold sold 1,972 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $32.27, for a total value of $63,636.44. Following the completion of the sale, the insider now directly owns 91,664 shares in the company, valued at $2,957,997.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Kristen M. Oelschlager sold 12,989 shares of Castle Biosciences stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $23.06, for a total value of $299,526.34. Following the transaction, the chief operating officer now directly owns 132,836 shares in the company, valued at approximately $3,063,198.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,476 shares of company stock worth $1,181,637. 7.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and issued a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Robert W. Baird boosted their target price on Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 6th. Finally, BTIG Research lifted their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $34.00.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $31.37 on Friday. The firm has a market cap of $866.03 million, a PE ratio of -27.28 and a beta of 1.03. The company’s fifty day simple moving average is $30.00 and its two-hundred day simple moving average is $24.95. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12-month low of $12.35 and a 12-month high of $34.50.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.47. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. The company had revenue of $87.00 million for the quarter, compared to analysts’ expectations of $69.95 million. During the same quarter in the previous year, the company earned ($0.70) earnings per share. As a group, equities analysts expect that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.